Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Phase 1
Recruiting
- Conditions
- Relapsed/Refractory Lymphoma
- Interventions
- Drug: Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT05189093
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciense, Beijing, Beijing, China
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Waterstone Hanxbio Pty Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT04886271
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong, China
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Waterstone Hanxbio Pty Ltd
- Target Recruit Count
- 21
- Registration Number
- NCT04097769
- Locations
- 🇦🇺
St George Private Hospital, Kogarah, New South Wales, Australia
News
No news found